Please assess the completion status of the following clinical trial:

Trial Title: Citalopram in Treating Postmenopausal Women With Hot Flashes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Must meet 1 of the following criteria:~  * History of breast cancer~    * No current malignant disease~ * No history of breast cancer and refused estrogen replacement therapy due to perceived increased risk of breast cancer~* Bothersome hot flashes, defined as hot flashes ≥ 14 times/week and of sufficient severity to make the patient desire therapeutic intervention~* Presence of hot flashes ≥ 1 month prior to study entry~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Female~* Postmenopausal, as defined by 1 of the following criteria:~  * Absence of a menstrual period in the past 12 months~ * Bilateral oophorectomy~ * Absence of a menstrual period in the past 6 months with follicle-stimulating hormone (FSH) level \> 40 mIU/mL~* ECOG performance status 0-1~* Life expectancy ≥ 6 months~* Willing to provide blood samples during study participation~* No history of allergic or other adverse reactions to citalopram hydrobromide or other selective serotonin reuptake inhibitors (SSRIs)~* No documented mania or hypomania~PRIOR CONCURRENT THERAPY:~* At least 4 weeks since prior and no concurrent antineoplastic chemotherapy~* At least 4 weeks since prior and no concurrent androgens, estrogens, or progestational agents~* At least 3 months since prior antidepressant use, including Hypericum perforatum (St. John's wort)~* Concurrent tamoxifen, raloxifene, or aromatase inhibitors allowed if on a constant dose for ≥ 4 weeks and continuing medication during study period~* No other concurrent or planned agents for treating hot flashes (e.g., phenobarbital, megestrol, or clonidine)~  * Stable dose of vitamin E allowed as long as it was started \> 30 days prior to study entry~* Concurrent soy allowed~* Concurrent gabapentin allowed for reasons other than hot flashes if on a constant dose for ≥ 1 month and continuing during study period

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- low-dose citalopram hydrobromide (Type: EXPERIMENTAL): Patients receive 1 tablet of oral citalopram once daily in weeks 2-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies.
- medium-dose citalopram hydrobromide (Type: EXPERIMENTAL): Patients receive 1 tablet of oral citalopram once daily in week 2 and 2 tablets once daily in weeks 3-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies.
- high-dose citalopram hydrobromide (Type: EXPERIMENTAL): Patients receive 1 tablet of oral citalopram once daily in week 2, 2 tablets once daily in week 3, and 3 tablets once daily in weeks 4-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies.
- placebo (Type: PLACEBO_COMPARATOR): Patients receive 1-3 placebo tablets once daily in weeks 2-7.~All patients complete a diary of hot flash incidence in weeks 1-7 and undergo blood collection periodically during study treatment for translational research studies.

Based on this trial design, predict the completion outcome and termination type (if applicable).